NIVF (NewGenIvf Group) Research & Development: $0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIVF NewGenIvf Group Ltd NIVF
14 GF Score
Price $1.12
! 4 Warning Signs
View Full Analysis

What is NewGenIvf Group Research & Development?

NewGenIvf Group NIVF -9.09% 14 Research & Development is $0.00 Mil as of Dec. 2025. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. NewGenIvf Group's Research & Development for the three months ended in Dec. 2025 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

NewGenIvf Group  (NAS:NIVF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NewGenIvf Group Research & Development Related Terms

NewGenIvf Group Research & Development Historical Data

* Premium members only.

The historical data trend for NewGenIvf Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewGenIvf Group Research & Development Chart

NewGenIvf Group Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 0.00 0.00 0.00 0.00

NewGenIvf Group Quarterly Data
Dec21 Dec22 Jun23 Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NIVF
14GF Score
NewGenIvf Group Ltd NIVF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewGenIvf Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.00 Mil mean?
NewGenIvf Group (NIVF) has a Research & Development of $0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on NewGenIvf Group and its competitors.
Is NewGenIvf Group's Research & Development too high?
NewGenIvf Group's current Research & Development is $0.00 Mil. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's Research & Development compare to RHEP and XCRT?
NewGenIvf Group's Research & Development of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on NewGenIvf Group and its competitors. NewGenIvf Group's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. NewGenIvf Group's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current Research & Development is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NewGenIvf Group Business Description

Address Sukhumvit 21 Road, Asoke, 36/39-36/40, 13th Floor, PS Tower, Khlong Toei Nuea Sub-district, Watthana District, Bangkok, THA, 10110
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score

Get the complete analysis for NIVF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.12
Price